Ventilator-associated pneumonia caused by ESKAPE organisms: Cause, clinical features, and management

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 3, 2012, Pages

  Sandiumenge, Alberto ^a   Rello, Jordi ^b  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

ESKAPE; methicillin resistant Staphylococcus aureus; multiresistant organisms; respiratory infections; ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLISTIN; DAPTOMYCIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; QUINOLONE DERIVATIVE; RIFAMPICIN; SULBACTAM; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CLINICAL FEATURE; DISEASE COURSE; DRUG MEGADOSE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCUS FAECIUM; HUMAN; INFECTION PREVENTION; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TRACHEOBRONCHITIS; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECIUM; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, VENTILATOR-ASSOCIATED; STAPHYLOCOCCUS AUREUS;

EID: 84859171064     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328351f974     Document Type: Review

References (94)

1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197:1089-1091.
2. Boucher HW, Talbot GH, Bradley S, et al. Bad bugs, nodrugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
3. Peterson LR. Bad bugs, nodrugs: no ESCAPE revisited. Clin Infect Dis 2009; 49:49.
4. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51:S81-S87. This is the review of the medical and microbiology literature and the results of the SENTRY Antimicrobial Surveillance Program (1997-2008) to establish the pathogens most likely to cause HAP or VAP.
5. Vincent JL, Rello J, Marshall J, et al., EPIC IIGroup of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
6. Chung DR, Song JH, Kim SH et al. High prevalence of multidrug-resistant non-fermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184:1409-1417.
7. ENVIN-HELICS informe 2010. http://hws.vhebron.net/envin-helics/Help/ Informe%20ENVIN-UCI%202010.pdf. [Accessed 30 November 2011]
8. Sandiumenge A, Lisboa T, Gomez F, et al. Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE organisms. Chest 2011; 14:645-651. This is the first study detailing the contribution of ESKAPE on VAP on a set of 2156 mechanically ventilated patients in whom different antimicrobial strategies for the empirical treatment of VAP were implemented during a 4-year period. The authors reported that strategies favoring antimicrobial diversity protected against the emergence and spread of resistance in ESKAPE pathogens.
9. Damas P, Layios N, Seidel L, et al. Severity of ICU-acquired pneumonia according to infectious microorganisms. Intensive Care Med 2011; 37: 1128-1135. This is a prospective study on 453 adult patients with ICU-acquired pneumonia in which the specific contribution of the etiological agent on outcome was measured.
10. Kimura Y, Kobayashi I. A case of pneumonia due to Enterococcus faeccium after near drowing. Kansenshogaku Zasshi 2011; 85:380-383.
11. J. Rello, M. Ulldemolins, T. Lisboa et al.; and the EU-VAP/CAP Study Group. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011; 37: 1332-1339. This is the secondary analysis of the EU-VAP study reporting variables associated with antibiotic prescription for VAP caused for different organisms.
12. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due toStaphylococcus aureus: a comparison of disease caused by methicillinresistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171-1175.
13. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008; 31:625-632.
14. Hanberger H, Walther S, Leone M, et al. Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents 2011; 38:331-335. This is a subanalysis of impact of MRSA in the EPIC II study. Authors conclude stating that in ICU patients, MRSA infection is independently associated with an almost 50% higher likelihood of hospital death compared with MSSA infection.
15. Rello J. What's new in respiratory infections in the intubated patient. In: Proceedings of the Conference at Congreso Panamericano e Iberico de Medicina Intensiva; Decemeber 2011; Cartagena de Indias, Colombia.
16. Vidaur L, Planas K, Sierra R, et al. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest 2008; 133:625-632. (Pubitemid 351367369)
17. Walkey AJ, O?Donnell MR, Wiener RS.Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controled trials. Chest 2011; 139:1148-1155. This is a systematic review and meta-analysis of all prospective randomized controlled trials in English language comparing glycopeptides over linezolid for the treatment of suspected MRSA nosocomial pneumonia. Authors conclude that linezolid is not superior over glycopeptide antibiotics for the treatment of nosocomial pneumonia, recommending choosing the treatment based on local availability, antibiotic resistance patterns, preferred routes of delivery, and cost, rather than presumed differences in efficacy.
18. Shime N, Kosaka T, Fujita N. The importance of ajudicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 2010; 29:1475-1479.
19. Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38:175-180.
20. Zephyr Study. Largest (phase IV) randomized clinical trial comparing linezolid with vacomycin for MRSA pneumonia. Clin Infect Dis (in press).
21. Freire AT, Meinyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/ cilastatin for the treatement of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140-151.
22. Rubinstein E, Corey GR, Sryjewski ME. Telavancin for the treatment of serious graum-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother 2011; 12:2737-2750. Authors review the pharmacokinetics, dosing, preclinical studies and clinical efficacy and safety of telavancin, with a particular focus on results from trials in nosocomial pneumonia
23. Koulenti D, Lisboa T, Brun-Buisson C, et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009; 37: 2360-2368.
24. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649-655. (Pubitemid 40684982)
25. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multiresistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-1118. (Pubitemid 36549630)
26. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acientobacter baumannii infections: epidemiology and treatment.Curr Opinion Infect Dis2010; 23:332-339. This is a review on clinical characteristics and therapeutic options of A. baumannii infections.
27. Marti S, Sanchez-Cespedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents 2009; 33:181-182.
28. Shio-Shin J, Ro-Ren H. Current review of antimicrobial treatment of nosocomial pneumonia caused by mutidrug-resistant pathogens. Expert Opin Pharmacother 2011; 12:2145-2148. This is an update on management of drug-resistant VAP.
29. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007; 39:38-43. (Pubitemid 46277146)
30. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56:432-436.
31. Dijkshoorn L, Nemec A, Seifert H. An increasing threat inhospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5:939-951. (Pubitemid 350131182)
32. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31:1058-1065. (Pubitemid 41125336)
33. Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007; 30:307-313. (Pubitemid 47194183)
34. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61:417-420.
35. Chastre J, Luyt CE. Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia. Clin Infect Dis 2010; 51:S54-S58. This is a review and recommendations on the design of newer trials on VAP.
36. Fujitani S,Sun HY,Yu V, et al. Pneumonia due toPseudomonas aeruginosa. Part I: Epidemiology, clinical diagnosis and Source. Chest 2011; 139:909-919. This is a comprehensive review on Pseudomonas pneumonia.
37. Bou R, Lorente L, Aguilar A, et al. Hospital economic impact of an outbreak of Pseudomonas aeruginosa infections. J Hosp Infect 2009; 71:138-142.
38. El Solh AA, Akinnusi ME, Wiener-Kronish JP, et al. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008; 178:513-519.
39. Berra L, Sampson J, Wiener-Kronish J. Pseudomonas aeruginosa: acute lung injury or ventilator-associated pneumonia. Minerva Anestesiol 2010; 76:824-832. This is a provocative study assessing the contribution of P. aeruginosa to VAP or acute lung injury.
40. Montero M, Sala M, Riu M, et al. Risk factors for multi drug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study. Eur J Clin Microbiol Infect Dis 2010; 29:335-339.
41. Riou M, Carbonnelle S, Avrain L, et al. In vivo developmentof antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 2010; 36:513-522.
42. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrugresistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43-48. (Pubitemid 43042900)
43. Ziberberg M, Chen j, Mody S et al. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 2010; 10:45. This is a meta-analysis of epidemiology and characteristics of resistant P. aeruginosa pneumonia.
44. Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007; 29:548-560. (Pubitemid 46372104)
45. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta-lactam aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database of Syst Rev 2006:CD003344. doi: 10.1002/14651858. CD003344.pub2.
46. Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010; 25:69-77. Prospective, observational computer-simulation of an approach considering ICUspecific antibiotic MICs coupled with pharmacodynamic dosing strategies in an ICU with high prevalence of resistant pathogens. Intervention resulted in improved outcomes and shorter duration of treatments.
47. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485.
48. Shwaber MJ, Carmeli Y. Mortality and delay ineffective therapy associated with extended-spectrum B-lactmase production in Enterobacteriaceae bacteriemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-920. (Pubitemid 47617735)
49. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumonia carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Anticrob Chemother 2010; 65:1119-1125.
50. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177. (Pubitemid 46084814)
51. George P, Morris AM. Pro/con debate: should antimicrobial stewardship programsbe adopted universally in the intensive care unit? Crit Care 2010; 14:205. Controversy on the contribution of stewardship programs in clinical practice.
52. Sun HR, Lu X, Ruan S. Qualitative analysis of models with different treatment protocols to prevent antibiotic resistance. Math Biosci 2010; 2010:56-67.
53. Sandiumenge A, Diaz E, Rodriguez A, et al. Impact of diversity of antibiotic use on development of antimicrobial resistance. J Antimicrob Chemother 2006; 57:1197-1203.
54. Agrafiotis M, Siempos II, Ntaidou TK, Falagas ME. Attributable mortality of ventilator-associated pneumonia: a meta-analysis. Int J Tuberc Lung Dis 2011; 15:1154-1163.
55. Aubron C, Chaari A, Bronchard R, Armand-Lefevre L, et al. High level cephalosporin-resistant Enterobacteriaceae ventilator- associated pneumonia: prognostic factors based on a cohort study. J Hosp Infect 2011; 77:64-69.
56. Barbier F, Wolff M. Multi-drug resistant Pseudomonas aeruginosa: towards therapeutic dead end. M S-Med Sci 2010; 26:960-968.
57. Berra L, Sampson J, Wiener-Kronish J. Pseudomonas aeruginosa: acute lung injury or ventilator-associated pneumonia. Minerva Anestesiol 2010; 76:824-832. [39]
58. Blot S, Rello J, Vogelaers D. What isnew in the prevention of ventilator-associated pneumonia. Curr Opin Pulm Med 2011; 17:155-159.
59. Carrillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, et al. Staphylococcus aureus Pneumonia in Children in the Era of Community-acquired Methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J 2011; 30:545-550.
60. Carron M, Freo U, Zorzi M, Ori C. Predictors of failure of noninvasive ventilation in patients with severe community- acquired pneumonia - art. no. 540.e9. J Crit Care 2010; 25:E9.
61. Chastre J, Luyt CE. Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia. Clin Infect Dis 2010; 51:S54-S58. [35]
62. Damas P, Layios N, Seidel L, et al. Severity of ICU-acquired pneumonia according to infectious microorganisms. Intensive Care Med 2011; 37:1128-1135. [09]
63. Esperatti M, Ferrer M, Theessen A, Liapikou A, et al. Nosocomial Pneumonia in the Intensive Care Unit Acquired by Mechanically Ventilated versus Nonventilated Patients. Am J Respir Crit Care Med 2010; 182:1533-1539.
64. Fujitani S, Sun HY, Yu V, et al. Pneumonia due toPseudomonas aeruginosa. Part I: Epidemiology, clinical diagnosis and Source. Chest 2011; 139:909-919. [36]
65. Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia Due toPseudomonas aeruginosa Part I: Epidemiology, Clinical Diagnosis, and Source. Chest 2011; 139:909-919.
66. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acientobacter baumannii infections: epidemiology and treatment. Curr Opinion Infect Dis 2010; 23:332-339. [26]
67. George P, Morris AM. Pro/con debate: should antimicrobial stewardship programs be adopted universally in the intensive care unit? Crit Care 2010; 14:205. [51]
68. Hanberger H,Walther S, Leone M, et al. Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents 2011; 38:331-335. [14]
69. Hibbard ML, Kopelman TR, O'Neill PJ, Maly TJ, et al. Empiric, Broad-Spectrum Antibiotic Therapy with an Aggressive De-Escalation Strategy Does Not Induce Gram-Negative Pathogen Resistance in Ventilator-Associated Pneumonia. Surg Infect 2010; 11:427-432.
70. Hota B, Lyles R, Rim J, Popovich KJ, et al. Predictors of clinical Virulence in Community-Onset Methicillin-Resistant Staphylococcus aureus Infections: The Importance of USA300 and Pneumonia. Clin Infect Dis 2011; 53:757-765.
71. J Rello, M Ulldemolins, T Lisboa, et al. the EU-VAP/CAP Study Group. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011; 37:1332-1339. [11]
72. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51:S81-S87. [04]
73. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, et al. Aerosolized plus Intravenous Colistin versus Intravenous Colistin Alone for the Treatment of Ventilator-Associated Pneumonia: A Matched Case-Control Study. Clin Infect Dis 2010; 51:1238-1244.
74. Lu Q,Yang JX, Liu ZH, Gutierrez C, et al. Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184:106-115.
75. Magnotti LJ, Croce MA, Zarzaur BL, Swanson JM, et al. Causative Pathogen Dictates Optimal Duration of Antimicrobial Therapy for Ventilator-Associated Pneumonia in Trauma Patients. J Am Coll Surg 2011; 212:476-484.
76. McMillian WD, Bednarik JL, Aloi JJ, Ahern JW, et al. Utility of ampicillin-Sulbactam for Empiric Treatment of Ventilator- Associated Pneumonia in a Trauma Population. J Trauma- Injury Infect Crit Care 2010; 69:861-865.
77. Nakwan N,Wannaro J, Thongmak T, Pornladnum P, et al. Safety inTreatment of Ventilator-Associated Pneumonia Due To Extensive Drug-Resistant Acinetobacter Baumannii With Aerosolized Colistin in Neonates: A Preliminary Report. Pediatr Pulmonol 2011; 46:60-66.
78. Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010; 25:69-77. [46]
79. Raad II, Mohamed JA, Reitzel RA, Jiang Y, et al. The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial- coated endotracheal tubes. Biomaterials 2011; 32:2689-2694.
80. Raineri E, Crema L, Dal Zoppo S, Acquarolo A, et al. Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2010; 29:1015-1024.
81. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65:2645-2649.
82. Rello J, Chastre J, Cornaglia G, Masterton R. A European care bundle for management of ventilator-associated pneumonia. J Crit Care 2011; 26:3-10.
83. Rello J, Ulldemolins M, Lisboa T, Koulenti D, et al. Determinants of prescription and choice of empirical therapy for hospital- acquired and ventilator-associated pneumonia. Eur Resp J 2011; 37:1332-1339.
84. Rubinstein E, Corey GR, Sryjewski ME. Telavancin for the treatment of serious graum-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother 2011; 12:2737-2750. [22]
85. Sandiumenge A, Lisboa T, Gomez F, et al. Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE organisms. Chest 2011; 14:645-651. [08]
86. Shio-Shin J, Ro-Ren H. Current review of antimicrobial treatment of nosocomial pneumonia caused by mutidrug-resistant pathogens. Expert Opin Pharmacother 2011; 12:2145-2148. [28]
87. Simon A,Tutdibi E, von Muller L, Gortner L. Ventilator-associated pneumonia in children. Monschr Kinderheilkd 2011; 159:224-232.
88. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia Due toPseudomonas aeruginosa Part II: Antimicrobial Resistance, Pharmacodynamic Concepts, and Antibiotic Therapy. Chest 2011; 139:1172-1185.
89. Toltzis P, Elward A, Davis D, Helfaer M, et al. Opportunities for antibiotic reduction in mechanically ventilated children. Pediatr Crit Care Med 2011; 12:282-285.
90. Venkatachalam V, Hendley JO, Willson DF. The diagnostic dilemma of ventilator-associated pneumonia in critically ill children. Pediatr Crit Care Med 2011; 12:286-296.
91. Vojtova V, Kolar M, Hricova K, Uvizl R, et al. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. New Microbiol 2011; 34:291-298.
92. Walkey AJ, ÓDonnell MR,Wiener RS.Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controled trials. Chest 2011; 139:1148-1155. [17]
93. Wilke MH, Grube RF, Bodmann KF. Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator- associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy. Eur J Med Res 2011; 16:315-323.
94. Ziberberg M, Chen j, Mody S, et al. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 2010; 10:45. [43]